Ruhrländer et al. (2026)
- Authors: Jana Ruhrländer, Elisabeth Schieffer, Bernhard Schieffer
- Institutes: Department of Cardiology, Angiology and Intensive Care Medicine, University Hospital Marburg (UKGM), Philipps University of Marburg, Marburg, Germany, Institute of Sports Medicine, Hannover Medical School, Hannover, Germany
- Publisher: Endocrine Reviews
- Link: DOI
Summary
This research bridges the gap between metabolic health and neurological symptoms in post-viral conditions, offering a new biological explanation for the debilitating fatigue and cognitive issues experienced by patients. By identifying specific hormone and neuropeptide pathways, the study opens the door for targeted treatments using already available medications. This provides a clear roadmap for future clinical trials focusing on metabolic and neuroendocrine restoration.
What was researched?
This review investigates the regulatory roles of the neuropeptide Orexin and the metabolic hormone Glucagon-Like Peptide-1 (GLP-1) in the context of post-viral syndromes like PASC and ME/CFS.
Why was it researched?
Post-viral syndromes lack a clear etiology, and researchers hypothesized that dysregulation of the neuroendocrine and metabolic systems may drive core symptoms like post-exertional malaise and autonomic dysfunction.
How was it researched?
The authors conducted an extensive literature review to construct a mechanistic model linking Orexin signaling and GLP-1 activity to the clinical features of post-viral diseases. They focused on phenotypic similarities and sexually dimorphic expression of these systems.
What has been found?
The study suggests that impaired Orexin signaling contributes to sleep-wake disturbances and metabolic failure, while Glucagon-Like Peptide-1 💊 provides neuroprotective and anti-inflammatory benefits. Researchers found that GLP-1 receptor agonists 💊 and drugs targeting the Orexin system 💊 show significant potential for managing the multisystem symptoms of ME/CFS.
Discussion
The paper notes that these metabolic pathways exhibit sexual dimorphism, which may explain why post-viral syndromes affect women more frequently. It emphasizes the clinical overlap between Orexin deficiency and the core features of PASC.
Conclusion & Future Work
Orexin and GLP-1 cycles provide a critical framework for understanding post-viral neuroendocrine-metabolic failure. Future research should prioritize clinical trials investigating the efficacy of metabolic modulators in this patient population.